Study suggests new molecular strategy for treating fragile X syndrome
Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and ...
The Pharma Letter5 天
Fragile X syndrome market to quadruple to $111.9 million in USA and Germany by 2030
According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to ...
MIT Neuroscientists Discover a Tiny Brain Receptor That Could Transform Fragile X Treatment
MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...
GEN2 天
Fragile X Phenotypes Reversed in Mice by Targeting NMDA Receptors
MIT researchers suggests a potential molecular strategy for treating fragile X syndrome by enhancing NMDA subunit function.
AZoLifeSciences on MSN1 天
Targeting NMDA Receptor Subunit Shows Promise for Fragile X Syndrome
Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and Memory reports a new way to treat pathology and symptoms of fragile X syndrome, ...
US and German FXS market forecast to grow by combined $83.2m from 2025 to 2030
A growth occurring in the next five years will be fuelled by the launch of two high-priced pipeline products providing ...
Stock prices and home values have created a ‘wealth effect,’ but the market is fragile ...
Surging stock prices and house values have fueled a remarkable increase in household wealth. Household net worth — the ...
Harmony Biosciences price target lowered to $42 from $52 at Mizuho
Mizuho lowered the firm’s price target on Harmony Biosciences (HRMY) to $42 from $52 and keeps an Outperform rating on the shares. The firm ...
MONTCO.Today on MSN2 天
Plymouth Meeting’s Harmony Biosciences Pivots After FDA Rejects Wakix for Sleep Disorder
Plymouth Meeting’s Harmony Biosciences’ stock fell 10% on Wednesday after the FDA rejected the expansion of its insomnia drug ...